Nine-Year Outcome of Ranibizumab Monotherapy for Choroidal Neovascularization Secondary to Pathologic Myopia
Conclusions: Long-term ranibizumab monotherapy treatment induces unchanged or better BCVA compared to baseline after a 9-year treatment in almost all eyes.Ophthalmologica
Source: Ophthalmologica - Category: Opthalmology Source Type: research
More News: Eyes | Lucentis | Myopia (short sighted) | Opthalmology | Ranibizumab Injection | Study | Women